CagriSema Body Transformation:
22.7% Weight Loss — Preview with AI
CagriSema combines two powerful mechanisms — amylin and GLP-1 — for ~50% more weight loss than semaglutide alone. See what your body could look like at 1, 3, 6, or 12 months.
Key Takeaways (REDEFINE-1 Phase 3 Data)
- Average weight loss on CagriSema: 22.7% of body weight over 68 weeks
- Dual mechanism combines cagrilintide (amylin analog) + semaglutide (GLP-1 agonist)
- Approximately 50% more weight loss than semaglutide (Wegovy) alone
- Two once-weekly injections (cagrilintide 2.4mg + semaglutide 2.4mg), with a single-injection formulation planned
- Developed by Novo Nordisk — Phase 3 complete, FDA review expected 2026-2027
What Is CagriSema?
CagriSema is a combination therapy developed by Novo Nordisk that pairs two distinct weight loss mechanisms in one treatment regimen:
- Cagrilintide — An amylin analog that enhances satiety by acting on brain centers controlling hunger and fullness, slowing gastric emptying, and reducing post-meal glucose spikes
- Semaglutide — A GLP-1 receptor agonist (the same active ingredient in Wegovy and Ozempic) that reduces appetite, slows digestion, and improves insulin sensitivity
By combining amylin and GLP-1 pathways, CagriSema achieves significantly greater appetite suppression and weight loss than either component alone. Currently administered as two separate once-weekly injections, Novo Nordisk is developing a single combined injection for greater convenience.
CagriSema Weight Loss Timeline
Based on REDEFINE-1 Phase 3 trial data (68 weeks), here is the expected weight loss timeline for someone starting at 230 lbs on the full dose:
| Timeline | Expected Weight Loss | Visual Changes |
|---|---|---|
| Month 1 | 4-7 lbs (2-3%) | Appetite drops significantly, reduced bloating, early changes |
| Month 3 | 15-25 lbs (7-11%) | Visible slimming, clothes noticeably looser, face thinning |
| Month 6 | 30-45 lbs (13-20%) | Dramatic body shape change, new wardrobe needed |
| Month 12 | 45-55 lbs (20-24%) | Approaching maximum effect, major transformation |
| Month 18+ | Up to 52+ lbs (22.7%) | Sustained weight maintenance at peak loss |
CagriSema vs. Wegovy vs. Ozempic vs. Mounjaro: Head-to-Head
CagriSema's dual mechanism delivers substantially more weight loss than semaglutide alone and competes with tirzepatide (Mounjaro) thanks to the added amylin pathway.
| Metric | Ozempic | Wegovy | Mounjaro | CagriSema |
|---|---|---|---|---|
| Avg weight loss | 14.9% | ~15% | 22.5% | 22.7% |
| Mechanism | GLP-1 | GLP-1 | GLP-1 + GIP | Amylin + GLP-1 |
| Key trial | STEP-1 | STEP-1 | SURMOUNT-1 | REDEFINE-1 |
| Dosing | Weekly injection | Weekly injection | Weekly injection | 2 weekly injections* |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly | Novo Nordisk |
| FDA status | Approved | Approved | Approved | Phase 3 complete |
*Single combined injection formulation in development
Use our GLP-1 & Peptide Weight Loss Calculator to compare projected timelines for all medications based on your starting weight.
CagriSema Dosing Schedule
CagriSema is currently administered as two separate once-weekly subcutaneous injections (cagrilintide and semaglutide). Both components follow a parallel dose escalation schedule:
| Weeks | Cagrilintide Dose | Semaglutide Dose | Phase |
|---|---|---|---|
| Weeks 1-4 | 0.25 mg | 0.25 mg | Initiation |
| Weeks 5-8 | 0.5 mg | 0.5 mg | Escalation |
| Weeks 9-12 | 1.0 mg | 1.0 mg | Escalation |
| Weeks 13-16 | 1.7 mg | 1.7 mg | Escalation |
| Week 17+ | 2.4 mg | 2.4 mg | Target / Maintenance |
Frequently Asked Questions
How much weight can you lose on CagriSema?
In the Phase 3 REDEFINE-1 trial, participants on CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) lost an average of 22.7% of their body weight over 68 weeks. For someone starting at 230 lbs, that translates to approximately 52+ lbs of weight loss.
Is CagriSema better than Wegovy alone?
Yes. Adding cagrilintide (an amylin analog) to semaglutide increases weight loss by approximately 50% compared to semaglutide (Wegovy) alone. In clinical trials, CagriSema achieved 22.7% weight loss vs approximately 15% with Wegovy. The dual amylin + GLP-1 mechanism provides superior appetite suppression and satiety.
When will CagriSema be available?
CagriSema completed its Phase 3 REDEFINE-1 trial with positive results. Novo Nordisk is expected to submit for FDA approval, with a review expected in 2026-2027. Until then, you can preview your potential results with BeforeAfterFit's AI visualization tool.
What is the difference between CagriSema and Wegovy?
CagriSema combines two distinct mechanisms — cagrilintide (an amylin analog) plus semaglutide (a GLP-1 agonist) — while Wegovy contains only semaglutide (a GLP-1 agonist). The added amylin pathway enhances feelings of fullness and slows gastric emptying through a complementary mechanism, resulting in approximately 50% more weight loss than Wegovy alone.
Related Resources
- All 9 Peptides Compared
- GLP-1 Weight Loss Calculator
- Ozempic Transformation
- Mounjaro Transformation
- Retatrutide Transformation
- Survodutide Transformation
- Orforglipron Transformation
- Pemvidutide Transformation
- Water Fasting Results
- Semaglutide vs Tirzepatide Comparison
- GLP-1 Weight Loss Timeline: Month by Month
- What Does 50 Pounds of Weight Loss Look Like?
- Wegovy Weight Loss Calculator
Medical Disclaimer: BeforeAfterFit is a visualization and motivation tool only. It does not provide medical advice. CagriSema (cagrilintide + semaglutide) is not yet FDA-approved for weight loss. Always consult your healthcare provider before starting any medication. Clinical trial results may not reflect individual outcomes.